Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 12Completed 10Unknown 8Terminated 3Not yet recruiting 3Active not recruiting 3Enrolling by invitation 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Non-Small-Cell Lung 1

Interventions

camrelizumab 2Radiotherapy 2Paclitaxel 2Cisplatin 2Carboplatin 2tislelizumab 1pembrolizumab 1nimotuzumab 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Omeprazole 1Loperamide 1High-Energy Shock Waves 1Gastroscopy 1Esophagectomy 1Drug Therapy 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × Esophageal Squamous Cell Carcinoma × Carboplatin × Clear all
NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06303583 2024-03-12

CRIS

Zhejiang Cancer Hospital

Phase 1/2 Enrolling by invitation
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡